secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027717
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS $384.2M; GAAP net income $159M
--------------------------------------------------------------------------------

- Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS contributed $384.2M; royalty from Roche $4.9M.
- GAAP net income $159.0M ($1.50 diluted EPS); non-GAAP net income $206.0M ($1.90 EPS).
- Full-year 2024 total revenues $1.9B (+53% YoY); GAAP net income $235.2M vs $536M net loss in 2023.
- 2025 net product revenue guidance $2.9B-$3.1B (70% YoY growth); ELEVIDYS expected to grow 162%.
- Closed Arrowhead licensing deal for 4 clinical-stage siRNA programs; established $600M revolving credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017025027717/0000950170-25-027717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017025027717/srpt-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer